157115-85-0
基本信息
N-(1-苯基乙?;?-L-脯氨酰胺甘氨酸乙酯
N-(1-(苯基乙酰基)-L-脯氨酰)甘氨酸乙酯
N-(1-(苯基乙?;?-L-脯氨酰)甘氨酸乙酯生產廠家
N-(1-(苯基乙?;?-L-脯氨酰) 甘氨酸乙酯 157115-85-0
SGS111
SGS-111
SGS 111
Noopept
CS-1723
Omberacetam
noopept powder
Noopept(GVS-111)
Nootropic GVS-111
物理化學性質
常見問題列表
N-(1-(苯基乙?;?-L-脯氨酰)甘氨酸乙酯的商品名NOOPEPT,作為治療肥胖、酒精依賴性退化或中毒性損傷等疾病。
Nooglutil exhibits pharmacologically significant competition with a selective agonist of AMPA receptors ([G-3H]Ro 48-8587) for the receptor binding sites (with IC50 = 6.4 +/- 0.2 microM), while the competition of noopept for these receptor binding sites was lower by an order of magnitude (IC50 = 80 +/- 5.6 microM) [1]. GVS-111 significantly increased neuronal survival after H(2)O(2)-treatment displaying a dose-dependent neuroprotective activity from 10 nM to 100 microM, and an IC(50) value of 1.21+/-0.07 microM. GVS-111 inhibited the accumulation of intracellular free radicals and lipid peroxidation damage in neurons treated with H(2)O(2) or FeSO(4), suggesting an antioxidant mechanism of action [2].
N-Phenylacetyl-L-prolylglycine ethyl ester (GVS-111) administered intravenously at a dose of 0.5 mg/kg/day, for the first time 1 h after ischaemic lesion and then for 9 post-operative days, with the last administration 15 min before testing, attenuated the deficit [3]. GVS-111 itself was not found in rat brain 1 h after 5 mg/kg i.p. administration up to limit of detection (LOD) under high performance liquid chromatography (HPLC) conditions [4]. The most pronounced antiinflammatory effect of dipeptide was observed on the model of adjuvant arthritis in rats, where the drug administered over 25 days in a daily dose of 0.5 mg/kg (i.m.) or 5 mg/kg (p.o.) significantly reduced the chronic immune inflammation (on the 12th day, by 94.0 and 74.1%, respectively) [5].